Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial

Abstract : The NEAT 001/ANRS 143 trial demonstrated non-inferiority of darunavir-ritonavir combined with either raltegravir (RAL+DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC+DRV/r) in HIV-positive, antiretroviral-naive adults. In post-hoc analyses however, RAL+DRV/r showed inferiority in patients with baseline CD4+ <200/mm and HIV-1 RNA ≥100,000 copies/mL. This pre-planned ancillary study was conducted to assess whether differences in adherence might explain efficacy results SETTING:: Phase III, open-label, randomized, multicentre study in 15 European countries (ClinicalTrials.gov, NCT01066962).
Document type :
Journal articles
Complete list of metadatas

https://hal.inria.fr/hal-01888899
Contributor : Laura Richert <>
Submitted on : Friday, October 5, 2018 - 2:27:11 PM
Last modification on : Tuesday, July 16, 2019 - 1:06:38 AM

Links full text

Identifiers

Collections

Citation

Adriana Ammassari, Wolfgang Stöhr, Andrea Antinori, Jean-Michel Molina, Christine Schwimmer, et al.. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial. Journal of Acquired Immune Deficiency Syndromes, Lippincott, Williams & Wilkins, 2018, ⟨10.1097/QAI.0000000000001834⟩. ⟨hal-01888899⟩

Share

Metrics

Record views

111